What is HC Wainwright's Forecast for LXEO Q1 Earnings?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Lexeo Therapeutics in a note issued to investors on Friday, May 16th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings of ($0.62) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $15.00 price target on the stock. The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.14) per share. HC Wainwright also issued estimates for Lexeo Therapeutics' Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.64) EPS, Q4 2026 earnings at ($0.65) EPS and FY2026 earnings at ($2.54) EPS.

A number of other analysts also recently weighed in on LXEO. Chardan Capital decreased their price target on Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Leerink Partners decreased their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a report on Monday, March 24th. Finally, Royal Bank of Canada decreased their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a report on Tuesday, March 25th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Lexeo Therapeutics has an average rating of "Buy" and an average target price of $20.20.

Lexeo Therapeutics Trading Down 8.4%

Lexeo Therapeutics stock traded down $0.26 during trading hours on Monday, reaching $2.82. 480,722 shares of the company's stock were exchanged, compared to its average volume of 490,973. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm's 50 day simple moving average is $3.09 and its 200 day simple moving average is $4.77. Lexeo Therapeutics has a twelve month low of $1.45 and a twelve month high of $19.50. The firm has a market capitalization of $93.62 million, a PE ratio of -0.89 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.19).

Hedge Funds Weigh In On Lexeo Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in LXEO. Affinity Asset Advisors LLC bought a new position in shares of Lexeo Therapeutics during the 1st quarter worth about $5,139,000. Millennium Management LLC boosted its position in shares of Lexeo Therapeutics by 654.8% during the 1st quarter. Millennium Management LLC now owns 1,071,489 shares of the company's stock worth $3,718,000 after purchasing an additional 929,538 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Lexeo Therapeutics by 15.3% during the 4th quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company's stock worth $28,508,000 after purchasing an additional 576,059 shares in the last quarter. Altium Capital Management LLC bought a new position in shares of Lexeo Therapeutics during the 4th quarter worth about $2,665,000. Finally, Point72 Asset Management L.P. boosted its position in shares of Lexeo Therapeutics by 102.5% during the 4th quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company's stock worth $4,937,000 after purchasing an additional 379,828 shares in the last quarter. Institutional investors own 60.67% of the company's stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.